JPRN-UMIN000019840已完成3 期
Treatment of Children with All Stage of Hepatoblastoma with Temsirolimus(IND#122782, NSC#683864) Added to High Risk Stratum Treatment - Treatment of Vincristine, Irinotecan, and Temsirolimus for Children with High Risk Hepatoblastoma (AHEP0731)
Children's Oncology Group0 个研究点目标入组 3 人开始时间: 2015年11月18日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 21years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients that have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastoma-directed therapy 2)Any prior chemotherapy 3)Currently receiving another therapy with other investigational drug 4)Currently receiving another anticancer agents 5)Previously received a solid organ transplant 6) Uncontrolled infection 7) Pregnant or breast feeding 8) Childbearing potential, not practicing adequate contraception 9)Receiving corticosteroids 10)Receiving enzyme inducing anticonvulsants 11)Receiving CYP3A4 inducers or inhibitors 12)Receiving therapeutic anticoagulants 13)Receiving ACE inhibitors 14) Patients who have had a major surgical procedure within 6weeks prior to registration 15) Patient who is judged inappropriate to participate in this study by the investigators.(ex; Patients don't sign informed concent.)
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the efficacy and tolerance of a chemotherapy by Idarubicin and Lipiodol emulsion administer in the liver, by the hepatic artery, on hepatocellular carcinoma.The research hypothesis is that hepatic locoregional treatment without embolization, using a more cytotoxic anticancer molecule (Idarubicin) than those conventionally used, would be more effective.MedDRA version: 20.0Level: LLTClassification code 10019828Term: Hepatocellular carcinoma non-resectableSystem Organ Class: 100000004864EUCTR2017-004859-22-FRniversity Hospital of Monptellier53
已完成
3 期
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver CancerPRETEXT I HepatoblastomaPRETEXT II HepatoblastomaPRETEXT III HepatoblastomaPRETEXT IV HepatoblastomaNCT00980460National Cancer Institute (NCI)236
进行中（未招募）
不适用
Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001)Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Rap-001) - treatment of HCC with rapamyciAdvanced hepatocellular carcinoma (HCC)EUCTR2004-002834-20-ATniversitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie30
尚未招募
不适用
Choices of therapeutic strategies for hepatocellular carcinoma (HCC)C22.0Liver cell carcinomaDRKS00025099Chirurgische Klinik, Universitätsmedizin Mannheim200
已完成
不适用
Clinical profile of hepatoblastoma.hepatoblastoma, surgery, outcomeHepatoblastomaTCTR20220418005Department of Surgical Gastroenterology23